scholarly journals Prognostic values of S100 family members in ovarian cancer patients

BMC Cancer ◽  
2018 ◽  
Vol 18 (1) ◽  
Author(s):  
Yang Bai ◽  
Liang-Dong Li ◽  
Jun Li ◽  
Xin Lu
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Family Members ◽  
S100 Family

scholarly journals Access to Genetic Testing Impacts Oncologists´ Decisions on Ovarian Cancer Personalized Treatment: Lessons Learned From a National Program in Greece

2018 ◽  
Vol 4 (Supplement 2) ◽  
pp. 74s-74s
Author(s):  
I. Boukovinas ◽  
G. Lypas ◽  
M. Liontos ◽  
C. Andreadis ◽  
C. Papandreou ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Genetic Counseling ◽  
Genetic Testing ◽  
Cancer Patients ◽  
Family Members ◽  
Brca2 Gene ◽  
Free Access ◽  
National Program ◽  
Mutation Carriers ◽  
Counseling And Testing

Background: State health insurance authorities in Greece do not reimburse genetic testing for cancer predisposition. The Hellenic Society of Medical Oncology has launched and carries out a national program covering genetic testing for BRCA1/2 mutations detection, with the financial support of pharmaceutical industry. Aim: This analysis evaluates how, during this program, access to genetic testing transformed the oncologists' therapeutic approach toward their ovarian cancer patients and how the results impacted treatment decisions concerning PARP inhibitors. Adoption of testing by healthy relatives and timing of testing in the disease continuum were also evaluated. Methods: Adult patients with high-grade epithelial ovarian carcinoma, irrespectively of family history or age at diagnosis were eligible for this program. Genetic counseling was recommended before testing, and both were offered at no financial cost. First degree family members of pathogenic mutation carriers were also offered free counseling and testing. Results: From March 2015 through January 2018, 708 patients were enrolled and tested. One hundred and forty seven (20.7%) mutation carriers were identified, 102 (14.4%) in BRCA1 and 45 (6.3%) in BRCA2 gene. Testing was more often pursued at initial diagnosis (61%) than at recurrence (39%), as recorded for 409 patients with available relevant information. During the 1st year of the program, average monthly tests performed were 25.1, while during the 3rd year this number increased to 34.3 tests per month. Among patients who tested positive for deleterious BRCA1/2 mutations, relapse was reported in 58 patients, 94.8% of which (n= 55) received treatment with the PARP inhibitor olaparib as per its indication. Family members of 21 patients (14.3%), out of the 147 who tested positive, received genetic counseling and testing for the mutation identified in the context of the program. Conclusion: Free access to genetic testing for BRCA1/2 for ovarian cancer patients and genetic consultation facilitates testing uptake, affects common clinical practice & has major impact on patients and their families. Still, diffusion of genetic information and broader testing of family members require further efforts by the oncological community.

scholarly journals Ovarian cancer patients’ and their family members’ perspectives on novel vaccine and virotherapy trials

2016 ◽  
Vol 13 (6) ◽  
pp. 660-664 ◽  
Author(s):  
Carmen Radecki Breitkopf ◽  
Jennifer L Ridgeway ◽  
Gladys B Asiedu ◽  
Katherine Carroll ◽  
Meaghan Tenney ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Family Members

scholarly journals The prognostic values of the peroxiredoxins family in ovarian cancer

2018 ◽  
Vol 38 (5) ◽  
Author(s):  
Saisai Li ◽  
Xiaoli Hu ◽  
Miaomiao Ye ◽  
Xueqiong Zhu
Keyword(s):  
Ovarian Cancer ◽  
Protein Expression ◽  
Cancer Patients ◽  
Expression Profiles ◽  
Family Members ◽  
Progression Free Survival ◽  
Prognostic Indicator ◽  
Chemotherapeutic Agents ◽  
Family Protein ◽  
Cancer Tissues

Purpose: Peroxiredoxins (PRDXs) are a family of antioxidant enzymes with six identified mammalian isoforms (PRDX1–6). PRDX expression is up-regulated in various types of solid tumors; however, individual PRDX expression, and its impact on prognostic value in ovarian cancer patients, remains unclear.Methods: PRDXs family protein expression profiles in normal ovarian tissues and ovarian cancer tissues were examined using the Human Protein Atlas database. Then, the prognostic roles of PRDX family members in several sets of clinical data (histology, pathological grades, clinical stages, and applied chemotherapy) in ovarian cancer patients were investigated using the Kaplan–Meier plotter.Results: PRDXs family protein expression in ovarian cancer tissues was elevated compared with normal ovarian tissues. Meanwhile, elevated expression of PRDX3, PRDX5, and PRDX6 mRNAs showed poorer overall survival (OS); PRDX5 and PRDX6 also predicted poor progression-free survival (PFS) for ovarian cancer patients. Furthermore, PRDX3 played significant prognostic roles, particularly in poor differentiation and late-stage serous ovarian cancer patients. Additionally, PRDX5 predicted a lower PFS in all ovarian cancer patients treated with Platin, Taxol, and Taxol+Platin chemotherapy. PRDX3 and PRDX6 also showed poor PFS in patients treated with Platin chemotherapy. Furthermore, PRDX3 and PRDX5 indicated lower OS in patients treated with these three chemotherapeutic agents. PRDX6 predicted a poorer OS in patients treated with Taxol and Taxol+Platin chemotherapy.Conclusion: These results suggest that there are distinct prognostic values of PRDX family members in patients with ovarian cancer, and that the expression of PRDX3, PRDX5, and PRDX6 mRNAs are a useful prognostic indicator in the effect of chemotherapy in ovarian cancer patients.

scholarly journals Survival in common cancers defined by risk and survival of family members

2011 ◽  
pp. 13-20
Author(s):  
Jianguang Ji ◽  
Asta Forsti ◽  
Kari Hemminki ◽  
Jan Sundquist ◽  
Per Lenner
Keyword(s):  
Ovarian Cancer ◽  
Nervous System ◽  
Cancer Patients ◽  
Genetic Factors ◽  
Family Members ◽  
Poor Survival ◽  
Risk Of Death ◽  
Swedish Family ◽  
Familial Cancers ◽  
Worse Prognosis

Studies on survival between familial and sporadic cancers have been inconclusive and only recent data on a limited number of cancers are available on the concordance of survival between family members. In this review, we address these questions by evaluating the published and unpublished data from the nation-wide Swedish Family-Cancer Database and a total of 13 cancer sites were assessed. Using sporadic cancer as reference, HRs were close to 1.0 for most of the familial cancers in both the offspring and parental generations, which suggested that survival in patients with familial and sporadic cancers was equal, with an exception for ovarian cancer with a worse prognosis. Compared to offspring whose parents had a poor survival, those with a good parental survival had a decreased risk of death for most cancers and HR was significantly decreased for cancers in the breast, prostate, bladder, and kidney. For colorectal and nervous system cancers, favorable survival between the generations showed a borderline significance. These data are consistent in showing that both good and poor survival in certain cancers aggregate in families. Genetic factors are likely to contribute to the results. These observations call for intensified efforts to consider heritability in survival as one mechanism regulating prognosis in cancer patients.

Immunoreactive score of Ep-CAM might predict survival in early ovarian cancer patients

2011 ◽  
Vol 71 (08) ◽  
Author(s):  
MJ Battista ◽  
J Steetskamp ◽  
N Mantai ◽  
S Gebhard ◽  
C Cotarelo ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Early Ovarian Cancer

ROLE OF LIPID PROFILE IN OVARIAN CARCINOMA PATIENTS

2019 ◽  
Vol 3 (8) ◽  
Author(s):  
Dr. Manisha ◽  
Dr. Ruchi Jindal
Keyword(s):  
Ovarian Cancer ◽  
Lipid Profile ◽  
Cancer Patients ◽  
Ovarian Tumor ◽  
Ovarian Cancer Risk ◽  
Low Level ◽  
Medical College ◽  
Group I ◽  
History Of

Background: The term "ovarian cancer" includes several different types of cancer that  arise from cells of the ovary, most commonly, tumors arise from the epithelium or lining cells of the ovary.  Ovarian cancer risk is positively associated with higher consumption of dietary cholesterol and eggs, and inversely associated with a higher intake of vegetables. High consumption of fats may increase circulating estrogen levels, thus increasing the possibility of cell damage and proliferation that is responsible for cancerous growth. Material & Methods: The present study was conducted at Geetanjali Medical College and Hospital, Udaipur (Rajasthan). Total  100 cases (females) attending the obstetrics and gynecology department for some gynecological and other problem  were selected for this study between the age of 40-60 years, who were attending cancer centre at GEETANJALI MEDICAL COLLEGE AND  HOSPITAL, Udaipur (Rajasthan).                GROUP I: - It consisted of healthy females control subjects (n=50) .By routine examination and tests, we ensured that all the subjects were healthy and there were no signs and symptoms or history of ovarian tumor and diseases GROUP II: - It consisted of ovarian cancer females subjects (n=50) with a history of ovarian tumor. Results:   Higher level of cholesterol, LDL, VLDL and low level of HDL are found in ovarian cancer patients. Conclusion: The present study we highlights the importance and role of serum lipid profile in diagnosis, prognosis and recurrence of the disease. The study shows that serum level of cholesterol, LDL, VLDL was elevated in  patients of ovarian cancer while low level of HDL are found in ovarian cancer patients. Key words: lipid profile, ovarian cancer.

Frequency of blood transfusions for anemia due to chemotherapy in ovarian cancer patients. Thoughts to the guidelines modified in 2006 for the treatment of anemic cancer patients by the European Organisation for Research and Treatment of Cancer

2007 ◽  
Vol 148 (45) ◽  
pp. 2133-2137 ◽  
Author(s):  
Ottó Lehoczky ◽  
Tamás Pulay
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Blood Transfusions ◽  
European Organisation

2006-ban jelent meg az Európai Rákkutatási és Kezelési Szervezet korábbi megállapításokat korszerűsítő ajánlása, amelyben a rákos betegekben kialakuló anémia kezelésére adott vértranszfúziót, illetve az ezt követő erythropoetin-kezeléseket értékelik. Az ajánlásban a vértranszfúziót a 9 g% hemoglobinszintre csökkenő anémia esetén javasolják. Eddig a kemoterápia következtében kialakult anémia vértranszfúziós kezelésére egyértelműen meghatározott hemoglobin-határértékszint Magyarországon nem szerepelt. Cél: A szerzők az osztályukon 2005-ben kezelt petefészekrákos betegeknek adott vértranszfúziók gyakoriságát vizsgálták. Nemzetközi, illetve hazai egyértelmű ajánlás hiányában a vizsgálati időszakban a vértranszfúziókat – a beteg klinikai állapotát is figyelembe véve – a 10 g%-ot elérő anémia esetén alkalmazták. Anyag és módszer: Az Országos Onkológiai Intézet Nőgyógyászati Osztályán 190 hám eredetű, petefészekrákos betegben történt kemoterápia. Ha a hemoglobinszint 10 g% alá csökkent, választott vörösvértest-transzfúziót végeztek, majd a betegek többségében (51/64 = 79,6%), erythropoetin-kezelés történt. Eredmény: A 190 közül 64 betegnél (64/190 = 34%) történt vérátömlesztés a kemoterápia kapcsán kialakult anémia miatt, s az utóbbiaknak csaknem felében (34/64 = 53%) 1-nél több alkalommal végeztek vértranszfúziót. A betegek 86%-ában a vértranszfúzióra G2-súlyosságú anémia miatt került sor. Az ismételten szükséges vértranszfúziókat a leggyakrabban a carboplatin-gemcitabin- (16/16) kezelések után alkalmazták. Következtetés: A petefészekrákokban adott kemoterápiák a betegek harmadában okoznak 10 g%-nál súlyosabb fokú anémiát. A vérszegénység kezelésében a vértranszfúzión kívül gondolni kell az erythropoetin-készítmények alkalmazására.

Sign in / Sign up

Export Citation Format

Share Document